Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
Research and Markets Announces the Release of 'Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities'
Publish date: Mar 20, 2013
![]()
PR Newswire DUBLIN, March 20, 2013
DUBLIN, March 20, 2013 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/t68g9q/autoimmune)
has announced the addition of the "Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and
Opportunities" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769
) As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The
complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically
ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective
treatment. But the convergence of improved understanding of autoimmune disease mechanisms and the availability of recombinant
cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control
autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise
of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact
on treatment options and the competitive landscape. Highlights: - Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses
their commercial potential - Assesses existing and evolving immune disease mechanisms and treatment strategies - Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific therapeutic drug products - Evaluates regional and global opportunities for autoimmune therapeutics - Provides market data and forecasts for six major autoimmune disease segments to 2016 Topics Covered: Executive Summary Autoimmune Therapeutics Segment Dynamics Sector Market Dynamics Autoimmune Therapeutic Market Assessments Arthritis Crohn's Disease Diabetes Lupus Multiple Sclerosis Psoriasis Autoimmune Therapeutics - Company Profile For more information visit http://www.researchandmarkets.com/research/t68g9q/autoimmune
Research and Markets SOURCE Research and Markets
|
|